Accu-Tell® COVID-19 IgG/IgM Rapid Test
[Linking template=”default” type=”products” search=”Accu-Tell Covid 19″ header=”4″ limit=”172″ start=”3″ showCatalogNumber=”true” showSize=”true” showSupplier=”true” showPrice=”true” showDescription=”true” showAdditionalInformation=”true” showImage=”true” showSchemaMarkup=”true” imageWidth=”” imageHeight=””]
For any query Contact Us Below:
Rapid Determination of SARS-CoV-2 Antibodies Using a Bedside, Point-of-Care, Serological Test
Background: Many fast serological assessments for SARS-CoV-2 have been developed or use, however misplaced have solely been validated on a few samples COVID-19 IgG/IgM Rapid Test, and none present medical practitioners with an easy-to-use, self-contained, bedside check with excessive accuracy.
Material and strategies: Two-hundred fifty-six sera from 101 sufferers hospitalized with SARS-CoV-2 an infection (optimistic RT-PCR) and 50 management sera had been checked for IgM/IgG utilizing the NG-Test IgM-IgG COVID all-in-one assay COVID-19 IgG/IgM Rapid Test. The seroconversion dynamic was assessed by symptom onset and day of RT-PCR analysis.
Results: Among the SARS-CoV-2 contaminated sufferers, optimistic IgG and/or IgM consequence was noticed for Accu-Tell COVID-19 IgG 67.3% of sufferers (68/101), together with 17 (16.8%) already optimistic on the day of RT-PCR, and 51 (50.5%) with observable seroconversion, and 32.7% (33/101) remained damaging as subsequent sampling was not attainable as a consequence of affected person COVID-19 IgG/IgM Rapid Test discharge or loss of life.
The sensitivity elevated with the delay between onset of signs and sampling, going from 29.1%, 78.2% and 86.5% for the time durations of 0-9-, 10-14- and >14-days after the onset of signs, respectively. Cumulative sensitivity, specificity, Positive Predictive Value and Negative Predictive Value had been 97·0%, 100%, 100% and 96·2%, respectively 15-days after the onset of signs.
No distinction in seroconversion delay was noticed no matter whether or not sufferers acquired air flow.
Conclusions: The NG-check is a bedside serological assay that would function a complementary supply of diagnostic info to RT-PCR and chest imaging COVID-19 IgG/IgM Rapid Test. It may additionally be helpful to watch immunological standing of medical and non-medical Accu-Tell COVID-19 IgG employees through the ongoing pandemic, and the final inhabitants after social distancing measures have eased.
Keywords: Bedside; COVID-19; Diagnosis; Diagnostics; Rapid Test; Serology.
Optimising triage procedures for sufferers with most cancers needing lively anticancer remedy within the COVID-19 period
Background: Immunosuppression induced by anticancer remedy in a COVID-19-positive asymptomatic affected person with most cancers could have a devastating impact and, ultimately, be deadly. To establish asymptomatic instances amongst sufferers receiving lively most cancers remedy COVID-19 IgG/IgM Rapid Test, the Federico II University Hospital in Naples performs fast serological assessments Accu-Tell COVID-19 IgG along with hospital customary scientific triage for COVID-19 an infection.
Methods: From 6 to 17 April 2020, all candidates for chemotherapy, radiotherapy or goal/immunotherapy, if damaging at the usual scientific triage on the day scheduled for anticancer remedy, acquired a fast serological check on peripheral blood for COVID-19 IgM and IgG detection COVID-19 IgG/IgM Rapid Test. In case of COVID-19 IgM and/or IgG positivity, sufferers underwent a real-time PCR (RT-PCR) SARS-CoV-2 check to substantiate an infection, and lively most cancers remedy was delayed.
Results: Overall 466 sufferers, damaging for COVID-19 signs, underwent serological testing along with customary scientific triage COVID-19 IgG/IgM Rapid Test. The common age was 61 years (vary 25-88 years). Most sufferers (190, 40.8%) had breast most cancers, and chemotherapy with or with out immunotherapy was administered in 323 (69.3%) sufferers.
Overall 433 (92.9%) sufferers had been IgG-negative and IgM-negative, and 33 (7.1%) had been IgM-positive and/or IgG-positive. Among the latter sufferers, 18 (3.9%), 11 (2.4%) and 4 (0.9%) had been IgM-negative/IgG-positive, IgM-positive/IgG-negative and IgM-positive/IgG-positive, respectively Accu-Tell COVID-19 IgG. All 33 sufferers with a optimistic serological check, examined damaging for RT-PCR SARS-CoV-2 check. No affected person in our cohort developed signs suggestive of lively COVID-19 an infection.
Conclusion: Rapid serological testing at hospital admission didn’t detect lively asymptomatic COVID-19 an infection. Moreover, it entailed further financial and human sources, delayed remedy administrationand elevated hospital accesses.
Keywords: SARS-CoV-2; most cancers; covid-19.
A comparative analysis between the Abbott Panbio™ COVID-19 IgG/IgM fast check gadget and Abbott Architect™ SARS CoV-2 IgG assay
Introduction: Antibodies to SARS-CoV-2 function important diagnostic markers for figuring out how broadly the COVID-19 pandemic has unfold, confirming affected person restoration, monitoring potential long-term results of an infection COVID-19 IgG/IgM Rapid Test, and evaluating potential safety from reinfection.
As new antibody assessments turn out to be out there, you will need to consider their efficiency and utility. The goal of this research was to match the efficiency of the Abbott PanbioTM COVID-19 gG/IgM RapidTest Device towards the Abbott ArchitectTM SARS CoV-2 IgG Assay for the detection of the COVID-19 IgG antibody.
Methods: Two panels of specimens had been utilized to problem each antibody assessments: (1) a set of 150 prepandemic damaging specimens collected in 2014, and (2) a set of 122 specimens from 87 hospitalized COVID-19 sufferers within the US and UK Accu-Tell COVID-19 IgG that had been confirmed with a optimistic SARS-CoV-2 RNA check consequence.
Results: The ArchitectTM check had a specificity of 100 % and sensitivity of 99.1 % and 93.9 % when excluding or together with immunocompromised sufferers, respectively for specimens collected >14 days submit symptom onset or >5 days post-RNA testing COVID-19 IgG/IgM Rapid Test. The PanbioTM check had 99.3 % settlement to ArchitectTM. Notably, N = 6 immune-compromised people had been recognized that didn’t develop detectable antibodies by day 30.
Conclusion: There is nice concordance between the ArchitectTM SARS CoV-2 IgG Assay and PanbioTM COVID-19 IgG/IgM Rapid Test Device for the detection of SARS CoV-2 IgG Accu-Tell COVID-19 IgG.
Keywords: Antibodies; COVID-19; Infection; SARS-CoV-2; Serology.